Adenoma, Islet Cell clinical trials
The registry lists 113 studies for Adenoma, Islet Cell across more than 10 countries. 30 are recruiting or about to start. 53 of them are mainly about Adenoma, Islet Cell (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its narrower condition Insulinoma too: 158 studies, 38 open.
Get an email when these change. Save the Adenoma, Islet Cell studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Dana-Farber Cancer Institute (5) · Fudan University (5) · National Cancer Institute (NCI) (4) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3) · Institut Paoli-Calmettes (2) · Pfizer (2) · Changhai Hospital (2) · Roswell Park Cancer Institute (2)
What is being tested here
Drugs under test in Adenoma, Islet Cell studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Temozolomide | 2 | 0 | 5 |
| Everolimus | 1 | 0 | 5 |
| Sunitinib | 1 | 0 | 4 |
| Capecitabine | 1 | 0 | 3 |
| Lutetium Lu 177 dotatate | 1 | 0 | 2 |
| SVN53-67/M57-KLH peptide vaccine | 1 | 0 | 2 |
| PM 01183 | 1 | 0 | 1 |
| Nimotuzumab | 1 | 0 | 1 |
| Belzutifan | 1 | 0 | 1 |
| Zanzalintinib | 1 | 1 | 1 |
Drug classes tested here Tyrosine kinase inhibitors (TKIs) 2 open · Alkylating agents 2 open · Angiogenesis inhibitors 1 open · Antimetabolites 1 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Dec 2026Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy · Phase 3 · RayzeBio, Inc.
- Sep 2027A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism · Phase 3 · Rezolute
- Nov 2026Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors · University of Chicago
- Dec 2026Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors · National Cancer Institute (NCI)
- Dec 2026Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001) · Shanghai Jiao Tong University School of Medicine
- Dec 2026A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors · David Bushnell
- Dec 2026Comparison of Kimura Versus Warshaw Technique for Laparoscopic Spleen-Preserving Distal Pancreatectomy · Fudan University
- Dec 2026Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms · University of California, San Francisco
- Feb 2027Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. · RayzeBio, Inc.
- Mar 2027Patients With High-grade Pancreatic Neuroendocrine Tumors · National Cancer Center, Korea
Who these studies take
Of the 24 Adenoma, Islet Cell studies recruiting now, 17 (71%) set no upper age limit and 2 (8%) stop at 75 or younger. 2 (8%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (13%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 24 (100%) | 24 (100%) |
| 30 | 24 (100%) | 24 (100%) |
| 40 | 24 (100%) | 24 (100%) |
| 50 | 24 (100%) | 24 (100%) |
| 65 | 24 (100%) | 24 (100%) |
| 75 | 24 (100%) | 24 (100%) |
| 85 | 19 (79%) | 19 (79%) |
Across all 113 studies, recruiting or not: 7% stop at 75 or younger and 2% at 65; 10% take children; 1% are for women only and 1% for men only; 4% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Adenoma, Islet Cell studies take
Of 17 phase 2 interventional studies under Adenoma, Islet Cell, half reached primary completion within 70 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 2 | 70 mo33–72 · 17 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
Studies
Recruiting first, then most recently updated. Showing 50 of 113. Browse all 113 → or search them.
- Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)RecruitingNCT04924075Phase 222 countries
- Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.RecruitingNCT07165132Phase 12 countries
- Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsRecruitingNCT06943755Phase 2/318 countries
- Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine CarcinomasNot yet recruitingNCT06202066Phase 21 country
- Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine TumorsRecruitingNCT05687123Phase 12 countries
- Endoscopic Ultrasound-Guided Pulsed Electric Field Ablation for the Treatment of Pancreatic NeoplasmsEnrolling by invitationNCT07619417Not applicable1 country
- Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a TumorAvailableNCT072629701 country
- A Phase 3 Study of Ersodetug in Patients With Tumor HyperinsulinismRecruitingNCT06881992Phase 35 countries
- Nutrition Intervention for Pancreatic CancerRecruitingNCT07554560Not applicable1 country
- Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)RecruitingNCT06141369Not applicable1 country
- Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic TumorsRecruitingNCT058478551 country
- Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid TumorsRecruitingNCT04119024Phase 11 country
- Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic DisordersRecruitingNCT008305571 country
- AI-Powered Precision Decision-Making for Pancreatic DiseasesRecruitingNCT074397571 country
- Genetic Predisposition Testing Program for Pancreatic Neuroendocrine NeoplasmsRecruitingNCT057461821 country
- Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or NotRecruitingNCT07273409Not applicable1 country
- Outcomes After Laparoscopic Versus Open PancreaticoduodenectomyRecruitingNCT07328607Not applicable1 country
- Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine TumorsRecruitingNCT06663072Phase 11 country
- Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine TumorsRecruitingNCT05040360Phase 23 countries
- Patients With High-grade Pancreatic Neuroendocrine TumorsEnrolling by invitationNCT07121478Phase 21 country
- Pancreatic Radiofrequency Under High Echo-endoscopy in the Management of Pancreatic Neuroendocrine TumorsRecruitingNCT04520932Not applicable1 country
- Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine TumoursRecruitingNCT061216221 country
- A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNETRecruitingNCT065929891 country
- Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other ExaminationsRecruitingNCT060410091 country
- Genetic Bases of Neuroendocrine Neoplasms in Mexican PatientsRecruitingNCT065235821 country
- Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine TumorsRecruitingNCT06472388Phase 21 country
- Comparison of Kimura Versus Warshaw Technique for Laparoscopic Spleen-Preserving Distal PancreatectomyNot yet recruitingNCT06167421Not applicable
- EUS-FNI for Nonfunctional Pancreatic Neuroendocrine TumorsRecruitingNCT05566093Not applicable1 country
- EUS-FNI for MEN1-related Pancreatic Neuroendocrine TumorsRecruitingNCT05554744Not applicable1 country
- Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine NeoplasmsNot yet recruitingNCT05316480Phase 21 country
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid TumorsActive, not recruitingNCT03375320Phase 31 country
- Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET TrialActive, not recruitingNCT05247905Phase 21 country
- Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA TherapyActive, not recruitingNCT05477576Phase 38 countries
- Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine TumorsCompletedNCT01824875Phase 21 country
- CT Radiomic Features of Pancreatic Neuroendocrine NeoplasmsCompletedNCT039679511 country
- Optimizing Risk Assessment Through cfDNA in Pancreatic Neuroendocrine Tumors for Clinical EvaluationActive, not recruitingNCT078172251 country
- Atezolizumab and Bevacizumab in Treating Patients With Rare Solid TumorsActive, not recruitingNCT03074513Phase 21 country
- Precision Radiotherapy Using MR-linac for Pancreatic Neuroendocrine Tumours in MEN1 PatientsActive, not recruitingNCT05037461Not applicable1 country
- Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR InhibitorsCompletedNCT05997056Phase 21 country
- A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine TumorsTerminatedNCT06158516Phase 21 country
- Multicenter Trial of ESK981 in Patients With Select Solid TumorsActive, not recruitingNCT05988918Phase 21 country
- A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function MutationsCompletedNCT05199584Phase 21 country
- Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine TumorsCompletedNCT03879694Phase 11 country
- Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal CancerCompletedNCT04505553Phase 21 country
- Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine TumorsActive, not recruitingNCT03891784Phase 21 country
- ATRX/DAXX in EUS-FNB Specimens of Pan-NETsActive, not recruitingNCT064063871 country
- Study of CVM-1118 for Patients With Advanced Neuroendocrine TumorsActive, not recruitingNCT03600233Phase 21 country
- A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine TumorsActive, not recruitingNCT06148636Early Phase 11 country
- Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT02159989Phase 11 country
- Neoadjuvant PRRT With Y-90-DOTATOC in pNETTerminatedNCT05568017Phase 21 country